Avinger Crescita futura

Future criteri di controllo 2/6

Si prevede che Avinger aumenterà gli utili e i ricavi rispettivamente del 22.4% e 30.2% all'anno, mentre si prevede che l'EPS crescerà del 58% all'anno.

Informazioni chiave

22.4%

Tasso di crescita degli utili

58.0%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.1%
Tasso di crescita dei ricavi	30.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	09 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:AVGR - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	18	-11	N/A	N/A	1
12/31/2025	14	-13	N/A	N/A	1
12/31/2024	7	-17	N/A	N/A	1
9/30/2024	7	-17	-15	-15	N/A
6/30/2024	7	-15	-15	-15	N/A
3/31/2024	8	-16	-15	-15	N/A
12/31/2023	8	-18	-14	-14	N/A
9/30/2023	8	-19	-14	-14	N/A
6/30/2023	8	-22	-14	-14	N/A
3/31/2023	8	-22	-15	-15	N/A
12/31/2022	8	-27	-17	-17	N/A
9/30/2022	9	-28	-18	-18	N/A
6/30/2022	9	-29	-18	-18	N/A
3/31/2022	9	-27	-17	-17	N/A
12/31/2021	10	-22	-16	-16	N/A
9/30/2021	10	-21	-15	-15	N/A
6/30/2021	10	-21	-15	-15	N/A
3/31/2021	9	-22	-15	-15	N/A
12/31/2020	9	-23	-15	-15	N/A
9/30/2020	9	-23	-15	-15	N/A
6/30/2020	9	-23	-16	-16	N/A
3/31/2020	10	-24	-16	-16	N/A
12/31/2019	9	-23	-17	-17	N/A
9/30/2019	9	-24	-17	-18	N/A
6/30/2019	8	-25	-17	-17	N/A
3/31/2019	8	-26	-18	-18	N/A
12/31/2018	8	-36	-18	-18	N/A
9/30/2018	8	-39	-20	-20	N/A
6/30/2018	8	-43	N/A	-24	N/A
3/31/2018	8	-49	N/A	-28	N/A
12/31/2017	10	-49	N/A	-34	N/A
9/30/2017	13	-52	N/A	-40	N/A
6/30/2017	16	-55	N/A	-44	N/A
3/31/2017	18	-55	N/A	-50	N/A
12/31/2016	19	-56	N/A	-53	N/A
9/30/2016	17	-56	N/A	-54	N/A
6/30/2016	15	-56	N/A	-55	N/A
3/31/2016	13	-53	N/A	-49	N/A
12/31/2015	11	-50	N/A	-41	N/A
9/30/2015	11	-44	N/A	-35	N/A
6/30/2015	11	-40	N/A	-28	N/A
3/31/2015	11	-37	N/A	-24	N/A
12/31/2014	11	-32	N/A	-22	N/A
9/30/2014	12	-32	N/A	-23	N/A
6/30/2014	12	-33	N/A	-27	N/A
3/31/2014	12	-37	N/A	-34	N/A
12/31/2013	13	-40	N/A	-41	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che AVGR rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che AVGR rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che AVGR rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di AVGR ( 30.2% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AVGR ( 30.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di AVGR è previsto essere elevato tra 3 anni

Avinger Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Price target decreased to US$8.50

Consensus forecasts updated

Analysts increase EPS estimates to -US$0.69

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Insufficient new directors

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avinger GAAP EPS of -$0.94 beats by $0.15, revenue of $2.13M misses by $0.25M

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

Is Avinger (NASDAQ:AVGR) A Risky Investment?

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Avinger shares fall after Q1 results fail to impress Wall Street

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Avinger Regains Compliance with Nasdaq Listing Requirements

Does Avinger (NASDAQ:AVGR) Have A Healthy Balance Sheet?

New 90-day high: US$0.89

Avinger 'Hot Penny Stock to buy' - Robinhood

New 90-day high: US$0.35

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Third quarter 2020 earnings released: US$0.079 loss per share

Revenue beats expectations, earnings disappoint

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.29

New 90-day low: US$0.29

Analysts increase EPS estimates to -US$0.69

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - US$0.67

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita